CBD Products

As federal hemp regulations tighten and state-by-state cannabis legalization accelerates, delta-9 THC gummies derived from hemp remain in legal gray territory—compliant under the 2018 Farm Bill’s 0.3% THC threshold by dry weight, yet subject to increased DEA scrutiny and conflicting state enforcement. We analyzed third-party lab results, extraction transparency, and manufacturing compliance across leading products to identify which producers prioritize COA authenticity over market positioning.

Cannabigerol (CBG) has transitioned from research compound to commercially viable cannabinoid, with 2026 offerings now achieving 15-25% CBG potency through advanced extraction. We evaluated leading products against third-party testing standards, federal compliance frameworks, and supply chain transparency.

As the pet CBD market expands beyond $1.2 billion annually, leading products demonstrate rigorous third-party testing, transparent cannabinoid profiles, and compliance with the 2018 Farm Bill’s <0.3% THC threshold—critical differentiators in a largely unregulated category where quality variance remains significant.

CBN (cannabinol) sleep gummies have emerged as a distinct category within the hemp-derived cannabinoid market, with leading products now offering transparent lab documentation and standardized dosing protocols. Third-party testing reveals significant variation in cannabinoid profiles and terpene inclusion across brands, directly impacting consumer outcomes and regulatory compliance standing.

Live resin cartridges have emerged as the premium segment of the legal cannabis market, commanding 35-40% price premiums over distillate products through superior terpene preservation and full-spectrum cannabinoid profiles. Independent lab testing reveals significant variation in potency claims and contamination risk across leading brands, making COA verification essential for informed purchasing.